Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
'Stealth' corporate innovation: an emerging threat for therapeutic drug development.
Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. Mastellos DC, et al. Among authors: risitano am. Nat Immunol. 2019 Nov;20(11):1409-1413. doi: 10.1038/s41590-019-0503-1. Nat Immunol. 2019. PMID: 31562490 Free PMC article.
Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development.
Mastellos DC, Blom AM, Connolly ES, Daha MR, Geisbrecht BV, Ghebrehiwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. Mastellos DC, et al. Among authors: risitano am. Nat Immunol. 2019 Nov;20(11):1556. doi: 10.1038/s41590-019-0531-x. Nat Immunol. 2019. PMID: 31605100
Applying complement therapeutics to rare diseases.
Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD. Reis ES, et al. Among authors: risitano am. Clin Immunol. 2015 Dec;161(2):225-40. doi: 10.1016/j.clim.2015.08.009. Epub 2015 Sep 1. Clin Immunol. 2015. PMID: 26341313 Free PMC article. Review.
Complement as a target in COVID-19?
Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD. Risitano AM, et al. Nat Rev Immunol. 2020 Jun;20(6):343-344. doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23. Nat Rev Immunol. 2020. PMID: 32327719 Free PMC article.
Author Correction: Complement as a target in COVID-19?
Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD. Risitano AM, et al. Nat Rev Immunol. 2020 Jul;20(7):448. doi: 10.1038/s41577-020-0366-6. Nat Rev Immunol. 2020. PMID: 32533108 Free PMC article.
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD. Mastellos DC, et al. Among authors: risitano am. Eur J Clin Invest. 2015 Apr;45(4):423-40. doi: 10.1111/eci.12419. Epub 2015 Mar 9. Eur J Clin Invest. 2015. PMID: 25678219 Free PMC article. Review.
205 results